Tech Center 1600 • Art Units: 1635 1674
This examiner grants 27% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17760908 | NUCLEIC ACID COMPLEX | Final Rejection | Takeda Pharmaceutical Company Limited |
| 18007560 | RNAI CONSTRUCTS FOR INHIBITING HSD17B13 EXPRESSION AND METHODS OF USE THEREOF | Non-Final OA | Amgen Inc. |
| 18065570 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF MICRORNA RELATED DISEASES | Final Rejection | HOFFMANN-LA ROCHE INC. |
| 17076607 | SPHERICAL NUCLEIC ACIDS WITH DENDRITIC LIGANDS | Non-Final OA | NORTHWESTERN UNIVERSITY |
| 18039630 | ADENINE BASE EDITOR HAVING INCREASED THYMINE-CYTOSINE SEQUENCE-SPECIFIC CYTOSINE EDITING ACTIVITY, AND USE THEREOF | Non-Final OA | Korea University Research and Business Foundation |
| 18063824 | CELLULAR UPTAKE OF FUNCTIONALIZED DNA NANOSTRUCTURES | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 16864130 | ORGAN DIRECTED GENE DELIVERY | Final Rejection | The Johns Hopkins University |
| 17542150 | GENERATION OF NEURONS BY REPROGRAMMING OF OLIGODENDROCYTES AND OLIGODENDROCYTE PRECURSOR CELLS | Non-Final OA | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL |
| 17050561 | METHODS AND COMPOSITIONS FOR TREATMENT OF HEMOPHILIA | Final Rejection | The University of North Carolina at Chapel Hill |
| 16324945 | A20 THERAPY TO ACHIEVE GLYCEMIC CONTROL | Non-Final OA | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. |
| 18106158 | CONJUGATED OLIGONUCLEOTIDE COMPOUNDS, METHODS OF MAKING AND USES THEREOF | Final Rejection | E-Therapeutics PLC |
| 18079262 | Nucleic acid-based membrane constructs for RNA polymerase detection | Non-Final OA | University of Seoul Industry Cooperation Foundation |
| 17174249 | INTRACELLULAR ABSEQ | Final Rejection | Becton, Dickinson and Company |
| 17784045 | INDUCTION OF PROLIFEROUS PANCREATIC ISLET PRECURSOR CELL-LIKE CELLS BY TRANSIENT EXPRESSION OF MYCL AND INDUCTION OF DIFFERENTIATION INTO INSULIN-POSITIVE CELLS | Non-Final OA | THE UNIVERSITY OF TOKYO |
| 16610408 | COMPOSITIONS AND METHODS OF USE OF ARC CAPSIDS | Non-Final OA | University of Utah Research Foundation |
| 18332415 | OLIGONUCLEOTIDE-BASED MODULATION OF C9orf72 | Final Rejection | UNIVERSITY OF MASSACHUSETTS |
| 16833107 | OLIGONUCLEOTIDE-BASED MODULATION OF C9orf72 | Final Rejection | UNIVERSITY OF MASSACHUSETTS |
| 17431887 | METHODS FOR DIAGNOSIS AND/OR THERAPY OF DISORDERS THAT CORRELATE WITH DENNDIA VARIANT 2 | Final Rejection | The Penn State Research Foundation |
| 18040834 | IN VIVO LYMPHOVENOUS ANASTOMOSIS | Final Rejection | THE TRUSTEES OF INDIANA UNIVERSITY |
| 17940988 | BIOMARKERS OF TRAUMATIC BRAIN INJURY | Final Rejection | THE UNIVERSITY OF BIRMINGHAM |
| 16664835 | GENE THERAPY FOR ALZHEIMER'S AND OTHER NEURODEGENERATIVE DISEASES AND CONDITIONS | Non-Final OA | Cornell University |
| 17772769 | DNMT1-Specific Aptamers and Production and Uses Thereof | Final Rejection | Consiglio Nazionale Delle Ricerche |
| 17999122 | VIRAL VECTORS AND NUCLEIC ACIDS FOR REGULATED GENE THERAPY | Non-Final OA | Boehringer Ingelheim International GmbH |
| 16748968 | Methods for Resensitizing p53-Null Cells to Cancer Chemotherapy | Final Rejection | UNIVERSITY OF SOUTH CAROLINA |
| 17615695 | APTAMERS AGAINST TRANSFERRIN RECEPTOR | Final Rejection | CITY OF HOPE |
| 16845280 | GENE-EDITING SYSTEMS FOR MODIFYING A SCN9A OR SCN10A GENE AND METHODS OF USE THEREOF | Final Rejection | Vertex Pharmaceuticals Incorporated |
| 17314909 | AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
| 18001241 | COMPOUNDS AND METHODS FOR REDUCING MSH3 EXPRESSION | Non-Final OA | Ionis Pharmaceuticals, Inc. |
| 17076195 | COMPOSITIONS, METHODS AND USES OF MESSENGER RNA | Final Rejection | Translate Bio, Inc. |
| 18183082 | RNA ENCODING A TUMOR ANTIGEN | Non-Final OA | CureVac SE |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy